Company Overview

American Shared Hospital Services (NYSE American: AMS) is a healthcare services company that provides advanced radiation therapy and related medical equipment solutions to hospitals and cancer treatment centers. The company primarily operates in the oncology and healthcare infrastructure sectors, focusing on stereotactic radiosurgery and radiation therapy systems used in cancer treatment. AMS generates revenue through long-term leasing arrangements, managed service agreements, and equipment ownership partnerships with healthcare providers.

The company’s principal business involves providing access to high-cost medical technologies, including Gamma Knife radiosurgery systems and proton beam radiation therapy systems, without requiring hospitals to make substantial upfront capital investments. AMS serves hospitals, academic medical centers, and specialty cancer treatment providers primarily in the United States and select international markets. Founded in 1983, the company evolved from a medical equipment leasing business into a specialized provider of advanced oncology treatment technologies, with strategic emphasis on radiation oncology infrastructure and long-duration healthcare partnerships.

Business Operations

AMS operates through healthcare equipment leasing and service arrangements centered on advanced radiation therapy technologies. Its major operational focus includes ownership and financing of Gamma Knife stereotactic radiosurgery systems and participation in proton beam therapy centers. The company earns revenue through contractual arrangements with healthcare institutions, including facility-based reimbursement participation, leasing fees, and service contracts tied to radiation oncology operations. Key assets include interests in proton therapy facilities and ownership stakes in radiation treatment equipment deployed at partner hospitals.

The company maintains both domestic and limited international operations. In the United States, AMS has partnered with hospitals and cancer centers to deploy radiosurgery systems and proton therapy capabilities. Internationally, the company has participated in proton therapy investments and treatment initiatives in regions including Asia. AMS has historically collaborated with equipment manufacturers such as Elekta AB, the producer of Gamma Knife systems, and has maintained ownership interests in affiliated treatment ventures and healthcare project entities connected to proton beam therapy development.

Strategic Position & Investments

AMS has positioned itself as a niche healthcare infrastructure and oncology technology financing company focused on specialized radiation treatment modalities. Its strategic direction emphasizes expanding access to advanced cancer treatment technologies through shared ownership models and long-term healthcare partnerships. A major area of investment has been proton beam therapy, which the company views as a long-duration growth opportunity within radiation oncology due to increasing clinical adoption and demand for precision cancer treatments.

The company has held investments and operational interests in proton therapy centers, including participation in projects associated with major healthcare systems and academic institutions. AMS has also continued investing in Gamma Knife technology upgrades and treatment center partnerships to maintain competitiveness in stereotactic radiosurgery. Public disclosures indicate that the company’s strategy prioritizes disciplined capital allocation, recurring revenue generation through service agreements, and selective expansion into emerging oncology treatment technologies where barriers to entry are relatively high due to equipment costs and clinical specialization.

Geographic Footprint

AMS is headquartered in San Francisco, California, and conducts the majority of its operations in the United States through partnerships with hospitals and cancer treatment providers. The company’s operational footprint includes healthcare institutions utilizing Gamma Knife and proton therapy technologies in multiple U.S. regions. Its business model is structured around long-term relationships with medical centers rather than broad direct-to-consumer healthcare delivery.

Beyond the United States, AMS has maintained involvement in international proton therapy investments and healthcare initiatives, particularly in parts of Asia. The company’s international exposure has historically been more investment-oriented than operationally extensive. While AMS does not maintain a global hospital network, its participation in advanced radiation oncology projects provides it with international investment visibility within specialized cancer treatment markets.

Leadership & Governance

AMS operates under a leadership structure focused on healthcare technology financing, oncology services, and long-term infrastructure investment. The company’s governance approach has emphasized operational discipline, strategic partnerships with healthcare providers, and measured expansion within high-cost oncology treatment sectors. Public filings and investor communications describe a strategy centered on recurring revenue generation, prudent capital management, and continued participation in advanced radiation therapy technologies.

Key executives include:

• Raymond Stachowiak – President and Chief Executive Officer
• John V. Rizzo – Executive Chairman
• Claire M. Green – Chief Financial Officer
• Daniel J. Fawcett – Senior Vice President of Operations

Leadership has consistently emphasized maintaining long-term hospital partnerships and expanding access to specialized cancer treatment technologies through flexible financing and shared-service arrangements. Some executive role details may vary over time based on recent filings and corporate disclosures; data is based on the latest publicly available company information and regulatory filings.